EP2391621A4 - BICYCLIC AMID DERIVATIVES FOR IMPROVING GLUTAMATERGIC SYNAPTIC RESPONSE - Google Patents

BICYCLIC AMID DERIVATIVES FOR IMPROVING GLUTAMATERGIC SYNAPTIC RESPONSE

Info

Publication number
EP2391621A4
EP2391621A4 EP10736150A EP10736150A EP2391621A4 EP 2391621 A4 EP2391621 A4 EP 2391621A4 EP 10736150 A EP10736150 A EP 10736150A EP 10736150 A EP10736150 A EP 10736150A EP 2391621 A4 EP2391621 A4 EP 2391621A4
Authority
EP
European Patent Office
Prior art keywords
responses
amide derivatives
bicyclic amide
enhancing synaptic
glutamatergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10736150A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2391621A2 (en
Inventor
Rudolf Mueller
Leslie J Street
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortex Pharmaceuticals Inc
Original Assignee
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharmaceuticals Inc filed Critical Cortex Pharmaceuticals Inc
Publication of EP2391621A2 publication Critical patent/EP2391621A2/en
Publication of EP2391621A4 publication Critical patent/EP2391621A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP10736150A 2009-02-02 2010-01-29 BICYCLIC AMID DERIVATIVES FOR IMPROVING GLUTAMATERGIC SYNAPTIC RESPONSE Withdrawn EP2391621A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20664209P 2009-02-02 2009-02-02
PCT/US2010/000255 WO2010087981A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Publications (2)

Publication Number Publication Date
EP2391621A2 EP2391621A2 (en) 2011-12-07
EP2391621A4 true EP2391621A4 (en) 2012-07-25

Family

ID=42396261

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10736150A Withdrawn EP2391621A4 (en) 2009-02-02 2010-01-29 BICYCLIC AMID DERIVATIVES FOR IMPROVING GLUTAMATERGIC SYNAPTIC RESPONSE

Country Status (12)

Country Link
EP (1) EP2391621A4 (https=)
JP (1) JP2012516845A (https=)
KR (1) KR20110115139A (https=)
CN (1) CN102369201A (https=)
AU (1) AU2010208646A1 (https=)
BR (1) BRPI1005316A2 (https=)
CA (1) CA2751285A1 (https=)
EA (1) EA018994B1 (https=)
IL (1) IL214392A0 (https=)
MX (1) MX2011008060A (https=)
SG (1) SG173168A1 (https=)
WO (2) WO2010087981A2 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367056A1 (en) * 1992-07-24 2003-12-03 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by AMPA receptors
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
DK1026950T3 (da) * 1997-10-27 2006-06-26 Univ California Behandling af skizofreni med ampakiner og neuroleptika
WO2008143963A1 (en) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
US8263591B2 (en) * 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
MX2011008060A (es) 2011-09-09
WO2010087980A2 (en) 2010-08-05
EA018994B1 (ru) 2013-12-30
WO2010087981A3 (en) 2011-03-24
SG173168A1 (en) 2011-08-29
AU2010208646A1 (en) 2011-09-01
BRPI1005316A2 (pt) 2019-09-24
EP2391621A2 (en) 2011-12-07
IL214392A0 (en) 2011-09-27
WO2010087980A3 (en) 2011-02-24
JP2012516845A (ja) 2012-07-26
EA201101162A1 (ru) 2012-01-30
KR20110115139A (ko) 2011-10-20
CN102369201A (zh) 2012-03-07
WO2010087981A2 (en) 2010-08-05
CA2751285A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
EP2154970A4 (en) DISUBSTITUTED AMIDS FOR IMPROVING GLUTAMATERGIC SYNAPTIC RESPONSE
FIC20200046I1 (fi) Alpelisibi tai sen suola
EP2168966A4 (en) BICYCLOANILINDERIVAT
ZA201001691B (en) Bicyclic amides for enhancing glutamatergic synaptic responses
EP2192109A4 (en) Bicyclic -amino acid derivative
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
EP2488876A4 (en) PROTEIN DETECTION VIA NANOREPORTER
EP2337587A4 (en) IMAGING AGENT FOR FIBROTIC DISEASES
BRPI1013016A2 (pt) &#34;métodos para identificação de locais para conjugação de igg&#34;
BR112012030067A2 (pt) disposuitivo sensor para ferramenta de inspeção de furo de poço&#39;
DK2326579T3 (da) Transportbånd med levende hængsel
BRPI0923401A2 (pt) Métodos para o preparo de aril amidas.
BRPI0906888A2 (pt) derivado de fenilacetamida
IL199651A0 (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
ZA200905065B (en) 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
EP2409977A4 (en) amide derivative
BRPI0812359A2 (pt) Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
EP2460796A4 (en) indole derivative
BRPI0814800A2 (pt) Derivados de aminoácidos
EP2463279A4 (en) amide derivative
BRPI0919200A2 (pt) derivado de aminoácido
BRPI1012581A2 (pt) derivados de amidas de ácido 6, 7-di-hidro-5h-imidazol[1,2-a]imidazol-3-carboxílico
BRPI0908283A2 (pt) Aparelho de soldagem
EP2391621A4 (en) BICYCLIC AMID DERIVATIVES FOR IMPROVING GLUTAMATERGIC SYNAPTIC RESPONSE
BRPI0912740A2 (pt) processos para a preparação de amidas

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110826

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

A4 Supplementary search report drawn up and despatched

Effective date: 20120626

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 451/02 20060101AFI20120620BHEP

Ipc: A61K 31/436 20060101ALI20120620BHEP

Ipc: A61P 25/00 20060101ALI20120620BHEP

Ipc: C07D 498/08 20060101ALI20120620BHEP

Ipc: C07D 413/06 20060101ALI20120620BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 451/02 20060101AFI20140619BHEP

Ipc: C07D 413/06 20060101ALI20140619BHEP

Ipc: A61P 25/00 20060101ALI20140619BHEP

Ipc: A61K 31/436 20060101ALI20140619BHEP

Ipc: C07D 498/08 20060101ALI20140619BHEP

INTG Intention to grant announced

Effective date: 20140721

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150429